As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
15 Analysts have issued a Phathom Pharmaceuticals Inc forecast:
15 Analysts have issued a Phathom Pharmaceuticals Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 147 147 |
460%
460%
|
|
| Gross Profit | 128 128 |
485%
485%
|
|
| EBITDA | -213 -213 |
26%
26%
|
|
| EBIT (Operating Income) EBIT | -213 -213 |
26%
26%
|
|
| Net Profit | -275 -275 |
19%
19%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
| Head office | United States |
| CEO | Steven Basta |
| Employees | 427 |
| Founded | 2018 |
| Website | www.phathompharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


